30 October 2018 - Pfizer CEO Ian Read said the company will return to “business as normal” on its drug pricing in January, after agreeing to hold off on price increases earlier this year following pressure from President Trump.

Read noted on an earnings call that the agreement to hold off on price increases would end at the end of the year, at which point the company will return to pricing based on the market. “We price to the marketplace, we price competitively,” Read said.

In July, Pfizer announced that it was holding off on planned price increases following a conversation between Read and Trump.

"Pfizer is rolling back price hikes, so American patients don't pay more," Trump tweeted at the time. "We applaud Pfizer for this decision and hope other companies do the same. Great news for the American people!"

Read The Hill article